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ABSTRACT 
 
Brown adipose tissue (BAT) has recently emerged as a novel target for obesity treatment 
and prevention. Cytochrome P450 (CYP) epoxygenases, primarily CYP2J and CYP2C isoforms, 
produce epoxy fatty acids (EpFAs), which have been suggested to play important roles in the 
regulation of white adipogenesis and obesity. However, adipocyte-specific expression of CYP 
epoxygenases has not been extensively analyzed, and the roles of CYP epoxygenases in brown 
adipogenesis remain unexplored. In this study, we examined mRNA levels of Cyp2j and Cyp2c 
isoforms during murine and human brown and white adipocyte differentiation and in various 
adipose tissue depots of high-fat diet (HFD)-fed and control mice. Moreover, we began to 
elucidate the roles of select CYP epoxygenases in brown adipogenesis through modulation of 
CYP expression. Stable transfection and lentiviral-mediated knockdown of murine Cyp2j13 and 
stable transfection of human CYP2J2 were performed in brown preadipocytes and their 
differentiation potentials were compared with cells that were transfected with empty vector or 
non-targeting knockdown controls. The effects on brown adipogenesis were evaluated by lipid 
accumulation and expression of brown adipocyte and general differentiation marker genes. We 
report that mRNA levels of CYP epoxygenases are increased in mature adipocytes compared to 
preadipocytes but decreased in the most strongly differentiated murine brown adipocytes. 
Furthermore, Cyp2j mRNA levels displayed an upward trend in the BAT of HFD-fed mice, 
implicating that Cyp2j expression may be associated with reduced BAT mass and activity. We 
show that Cyp2j13 overexpression significantly suppressed murine brown adipocyte 
differentiation, while Cyp2j13 knockdown enhanced differentiation, suggesting that Cyp2j13 
may be a negative regulator of brown adipogenesis. In contrast, CYP2J2 overexpression did not 
remarkably affect human brown adipocyte differentiation. Together, our results suggest that CYP 
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epoxygenases may play important roles in brown adipogenesis. Cyp2j13, in particular, may be a 
novel target for brown adipogenesis, and consequently, for obesity treatment and prevention. 
Further studies are warranted to examine the roles of CYP2J2 by gene knockdown and 
pharmacological antagonism, to determine whether CYP2J2 overexpression may alleviate 
inflammation-induced suppression of brown adipocyte differentiation and activity, and to 
analyze roles of other CYP epoxygenase isoforms in brown adipogenesis for obesity treatment 
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CHAPTER I  
INTRODUCTION 
 
The worldwide prevalence of obesity has nearly tripled from 1975 to 2016. In 2016, 
nearly 1.9 billion adults were overweight, and 650 million of these adults were obese [1]. As 
global rates of obesity continue to rise, it is of increasing importance to develop novel 
therapeutic strategies to combat this pandemic along with its accompanying comorbidities such 
as type 2 diabetes and cardiovascular disease. Obesity is fundamentally characterized by a 
chronic energy imbalance, in which energy storage exceeds energy expenditure [2]. White 
adipose tissue (WAT) is the principal site of energy storage in the body, accumulating excess 
energy in the form of lipid droplets [3, 4]. In contrast, brown adipose tissue (BAT) is a site of 
energy expenditure due to its thermogenic potential [5, 6]. Metabolically active BAT was 
previously thought to only exist in human infants, as a method of adaptation to cooler extra-
uterine temperatures following birth [5, 6]. More recently, significant amounts of functional 
BAT were found to be present in adult humans [7, 8]. This discovery has introduced a realm of 
research investigating strategies to manipulate the thermogenic capacity of BAT as a means of 
enhancing energy expenditure, thus aiding in reversal of the chronic energy imbalance that 
underlies obesity.  
Polyunsaturated fatty acids (PUFAs) are fatty acids that are metabolized into a variety of 
signaling molecules known as eicosanoids, which are key mediators of inflammation [9]. The 
cytochrome P450 (CYP) epoxygenase pathway of PUFA metabolism produces epoxy fatty acids 
(EpFAs) such as arachidonic acid (ARA)-derived epoxyeicosatrienoic acids (EETs), which exert 
anti-inflammatory, anti-oxidative stress, vasodilatory, and angiogenic actions by activating 
receptor-mediated signaling pathways and ion channels [10]. EETs and other EpFAs have been 
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demonstrated to produce favorable effects on obesity and its related metabolic diseases such as 
attenuation of high-fat diet (HFD)-induced increases in body weight, adiposity, serum lipids, 
insulin resistance, and vascular dysfunction, in numerous studies [10-13]. These metabolic 
effects are partially mediated through adipocyte-specific actions, as increasing EET 
concentrations in white preadipocytes has been shown to decrease their ability to differentiate 
and accumulate lipids [14]. CYP epoxygenase overexpression is one method of increasing EpFA 
production to elicit these positive outcomes [15]. However, the specific CYP isoforms expressed 
in adipocytes that contribute to EpFA production are not well characterized. Additionally, the 
role of CYP epoxygenases and subsequent EpFA production remains unexplored in brown 
adipocytes, and it is unclear if the observed metabolic benefits can be partially attributed to an 
increase in BAT development and activation. In the current study, we sought to determine which 
CYP epoxygenase isoforms are expressed in brown and white adipocytes throughout 
differentiation and in diet-induced obesity. Furthermore, we began to elucidate the role of CYP 
epoxygenases in brown adipogenesis through modulation of CYP expression in brown adipocyte 
differentiation. The results presented contribute to our understanding of adipocyte CYP 
epoxygenase expression and suggest a role of these enzymes in brown adipocyte differentiation. 
Together, this provides promising areas for future research to uncover methods to manipulate the 
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CHAPTER II  
LITERATURE REVIEW 
 
2.1. Adipose Tissue and Metabolic Homeostasis 
 
2.1.1. Types of Adipose Tissue 
 
Three major types of adipose tissue are recognized to exist in mammals, each of which 
plays different roles in metabolic homeostasis and obesity development. White adipose tissue 
(WAT) is distributed throughout the body, with its primary function being the storage of energy 
as triacylglycerols (TAG) and the release of this energy through lipolysis to free fatty acids 
(FFAs) and glycerol. WAT is considered an endocrine organ and regulates a variety of 
physiological processes through the synthesis and secretion of biologically active compounds, 
such as hormones and cytokines, which are deemed as adipokines [3, 4]. In circumstances of 
energy surplus, WAT possesses the ability to expand and proliferate through hypertrophy and 
hyperplasia in order to accommodate excess lipids. Excessive lipid accumulation is characteristic 
of obesity and prompts a state of chronic inflammation and oxidative stress in WAT, leading to a 
dysregulated gene expression profile and altered adipokine production, and ultimately driving the 
metabolic diseases associated with obesity [3, 4].  
 Brown adipose tissue (BAT) exists in discrete depots throughout the body and is 
histologically and functionally distinct from WAT. While white adipocytes are large in size with 
a unilocular lipid compartment, brown adipocytes are smaller with numerous lipid droplets [6, 
16, 17]. Most notably, brown adipocytes are far more concentrated in mitochondria, which gives 
the tissue its darker color and renders it more metabolically active. BAT possesses a unique 
protein on the inner membrane of its mitochondria known as uncoupling protein-1 (UCP1), 
which facilitates its ability to undergo non-shivering thermogenesis, a process of heat production. 
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In the electron transport chain, UCP1 uncouples the proton motive force from adenosine 
triphosphate (ATP) synthesis by allowing H+ to leak into the mitochondrial matrix, thus 
dissipating this energy as heat and elevating overall energy expenditure. BAT is highly 
vascularized to allow for delivery of substrates and oxygen to facilitate this heat production and 
in order to effectively transmit generated heat to other tissues in the body [5, 6, 16, 17].   
A third form of adipose tissue has also been described, in which adipocytes located 
within WAT can be recruited in response to various stimuli to express a BAT-like phenotype, 
with multilocular lipid droplets, increased mitochondria, and UCP1 expression, allowing these 
cells to facilitate thermogenesis much like classical brown adipocytes. These inducible brown 
adipocytes are referred to as beige adipocytes, and this process is known as the “browning” of 
WAT [18-20]. Despite similarities in thermogenic function, brown and beige adipocytes should 
be distinguished as different cell types due to numerous key discrepancies. Beige fat possesses a 
distinct gene expression pattern compared to classical BAT. In contrast with classical BAT, 
which elicits high basal UCP1 expression, expression of UCP1 in beige adipocytes is only 
present upon stimulation [18-20]. Additionally, a number of quantitative trait loci are associated 
with the induction of beige but not brown adipocyte development, signifying these cell types are 
likely differentially regulated [21]. The extent to which these beige fat cells comprise the 
functional BAT observed in adult humans is unknown [20], but nonetheless, both beige and 
brown adipocytes display exciting potential for therapeutic outcomes in obesity due to their 
energy expending capacity. 
2.1.2. Therapeutic Potential of Brown Adipose Tissue 
 
The ever-increasing global burden of obesity and scarcity of effective treatments has 
instigated a search for novel therapeutic targets. Due to its energy expending capacity, BAT 
   5 
holds great promise in this realm. BAT is inversely associated with body mass index, adiposity, 
and type 2 diabetes incidence [22], suggesting that increasing BAT mass and activity can 
ameliorate these conditions. It is estimated that approximately 50 grams of active BAT in 
humans could account for a 20% increase in daily energy expenditure [23], which corroborates 
the clinical relevance of enhancing BAT mass in obese individuals. BAT activity also decreases 
with age, with an estimated 50% activity in individuals in their 20s compared to approximately 
10% activity in those in their 50s and 60s [24]. This observation coincides with the known 
decrease in basal metabolic rate with advancing age, indicating potential for a more remarkable 
metabolic impact with enhanced activation in an older population [25].  
In addition to associational evidence in humans, BAT-mediated thermogenesis has 
demonstrated to directly impact body weight homeostasis in mouse models, with UCP1 ablation 
inducing obesity and its associated complications in mice when housed at thermoneutral 
conditions [26, 27]. Conversely, these mice did not become obese when housed at room 
temperature [28]. BAT elicits additional functions that may act alongside body weight reduction 
as a means to improve overall metabolic health. Namely, its ability to rapidly uptake and dispose 
of circulating lipids and glucose may attenuate insulin resistance and hyperlipidemia, both of 
which are commonly present in obese individuals [29, 30]. Together, this provides compelling 
evidence that research examining factors to promote BAT development and activation is 
warranted for its therapeutic potential in obesity. 
2.1.3. Brown Adipose Tissue Development and Activation 
 
Brown adipocytes, in addition to skeletal muscle cells and certain populations of white 
adipocytes, are derived from Myf-5-expressing myogenic precursors [6, 31]. Once mesenchymal 
stem cells (MSCs) are determined as preadipocytes, differentiation occurs to allow for 
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development of the morphological and functional characteristics of mature adipocytes. This 
adipocyte development process, including determination of stem cell fate and differentiation into 
mature adipocytes, is referred to as adipogenesis [32]. Although there are numerous transcription 
factors and other regulatory factors involved in the complex process of brown adipogenesis, 
peroxisome proliferator-activated receptor gamma (PPARg), PR domain containing protein 16 
(PRDM16), and PPAR gamma coactivator-1 alpha (PGC-1a) represent the key players involved. 
PPARg is a ligand-activated nuclear receptor which dimerizes with retinoid X receptor (RXR) 
and binds to peroxisome proliferator response elements (PPREs) to regulate expression of target 
genes [33]. PPARg is primarily expressed in adipose tissue and is considered the master regulator 
of adipogenesis, but also plays an integral role in the regulation of lipid metabolism, insulin 
signaling, and adipokine production, among other functions [33]. PPARa, another PPAR 
isoform, is more highly expressed in BAT rather than WAT and is predominantly involved in 
lipid metabolism. PPARa can also induce adipogenesis, although not to the same extent as 
PPARg [34]. 
As the master regulator of adipogenesis, PPARg is essential for the development of both 
brown and white adipocytes [35, 36]; however, this transcription factor alone is not sufficient to 
commit MSCs to a brown adipocyte lineage. Together with early B-cell factor 2 (EBF2), 
PPARg stimulates expression of PRDM16 [21]. PRDM16 operates as a molecular bidirectional 
switch to determine whether MSCs become myocytes or brown adipocytes [37]. Knockdown of 
PRDM16 in brown adipocytes results in a loss of thermogenic potential and differentiation of 
these cells into myocytes, whereas ectopic expression of this protein induces a thermogenic 
phenotype in myoblasts [37, 38]. PRDM16 binds to and modulates the activity of a number of 
transcription factors in brown preadipocytes that are imperative for differentiation and 
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stimulation of thermogenic activity, including PPARg and PGC-1a [6, 39]. PGC-1a is 
recognized as the chief controller of mitochondrial biogenesis and respiration and activates 
thermogenesis in BAT through stimulation of UCP1 expression [39, 40]. Although PGC-1a is 
essential for activation of thermogenic function in BAT, it is not believed to be involved in the 
commitment to the BAT lineage from Myf-5-expressing precursors, as BAT develops normally 
in PGC-1a-null mice [41].  
In addition to knowledge regarding molecular mechanisms of BAT development, 
comprehension of means to enhance BAT thermogenic activity is critical in order to unlock its 
therapeutic potential. BAT is highly innervated with sympathetic nervous fibers, and activation 
of the sympathetic nervous system (SNS) is recognized as a principal mechanism of BAT 
thermogenesis induction [5, 6]. Upon SNS activation, norepinephrine is released and binds to b3-
adrenergic receptors on the cell surface of brown adipocytes, which triggers an intracellular 
cascade resulting in the formation of cyclic adenosine monophosphate (cAMP) and subsequent 
activation of protein kinase A (PKA). PKA phosphorylates and activates hormone sensitive 
lipase (HSL), which initiates lipolysis, cleaving TAGs to FFAs and glycerol. These FFAs are 
shuttled to BAT mitochondria, where they can induce UCP1 activity and thermogenesis [17]. 
Aside from adrenergic stimulation, numerous other factors have been described to activate 
thermogenesis through interaction with various cell membrane and nuclear receptors in BAT, 
including thyroid hormones, irisin secreted from skeletal muscle, and natriuretic peptides 
released from the heart [21, 42].  
Cold exposure results in norepinephrine release and serves as the most well-established 
trigger for BAT thermogenesis, as a means to maintain body temperature [5]. Cold exposure not 
only promotes activation of classical BAT but is also known to stimulate formation of beige fat 
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to aid in heat production [18]. Despite its profound effects on BAT stimulation, increasing 
exposure to cold temperatures is not a practical method to improve BAT activity for obesity 
treatment. Numerous studies have elucidated roles of various dietary and pharmacological 
factors that may mimic the effect of cold exposure on BAT. Capsaicin and its analog capsinoids, 
compounds found in red peppers, are among the most heavily studied dietary factors 
demonstrated to augment BAT-mediated thermogenesis, through activation of the calcium 
channel transient receptor potential vanilloid 1 (TRPV1), which subsequently results in b3-
adrenergic stimulation [43, 44]. Consumption of high doses of capsinoids has demonstrated to 
enhance thermogenesis in both rodents and humans, and ingestion of 9 mg per day of capsinoids 
for six weeks resulted in greater cold-induced thermogenesis and decreased fat mass in human 
subjects [45]. A meta-analysis examining the impacts of capsinoids and capsaicin on humans has 
confirmed their ability to enhance energy expenditure and fat oxidation; however, the magnitude 
of these effects suggests only a small benefit for long-term weight loss, and many successful 
studies were conducted in lean individuals [46]. Fish oil, curcumin, green tea catechins, and 
resveratrol are among other dietary compounds with substantial evidence proposing a role in 
BAT activation, although numerous others have also been described [47]. Ultimately, there is 
significant potential for dietary compounds to act as therapeutic agents through increased BAT 
mass and activity, but further research is warranted in order to obtain clinically relevant 
outcomes for obesity. 
2.2. Polyunsaturated Fatty Acids and their Metabolites 
 
2.2.1. Overview of Polyunsaturated Fatty Acids: Structure, Function, Dietary Sources 
 
Fatty acids are generally categorized based upon the length of their carbon chain and the 
number of double bonds. Polyunsaturated fatty acids (PUFAs) are fatty acids that contain at least 
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two double bonds on their carbon chain. PUFAs can be further classified into n-3 and n-6 
PUFAs, indicating the position of the first double bond is three or six carbons from the methyl 
end of the carbon chain, respectively. The 18-carbon n-3 and n-6 PUFAs, alpha-linolenic acid 
(ALA) and linoleic acid (LA), are considered essential, indicating they cannot be synthesized in 
the body and must instead be obtained through dietary sources. Vegetable oils such as soybean 
oil, canola oil, and sunflower oil are especially concentrated in LA but also contain small 
proportions of ALA, whereas the opposite is true for flaxseed oil. These essential fatty acids can 
also be found in significant quantities in chia seeds, hemp seeds, and walnuts [48, 49].  
Longer chain (≥20 carbons) n-3 PUFAs, eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), and the n-6 PUFA arachidonic acid (ARA), are more biologically 
active and can be synthesized from ALA and LA through multiple steps of elongation and 
desaturation [48, 49]. However, this conversion rate is considered to be low in mammals, and 
many experts recommend obtaining these longer chain PUFAs directly from the diet to ensure 
biological processes are not compromised as a result of deficiency [50-52]. ARA is particularly 
abundant in most animal products, such as meat, cheese, and eggs. Insufficient intake of n-6 
PUFAs is not a concern for the general population, as typical Western diets are highly 
concentrated in both LA and ARA. EPA and DHA, on the other hand, can only be found in cold-
water oily fish, and as a result, there is a greater threat for deficiency in cultures where habitual 
seafood consumption is not typical [48, 49].  
PUFAs are involved in numerous functions throughout the body and have been 
extensively studied for their roles as inflammatory mediators. This ability to modulate levels of 
inflammation in the body is especially intriguing for therapeutic research, considering many of 
the health conditions that plague modern society are provoked and propagated through chronic 
   10 
low-grade inflammation. The n-6 PUFAs produce metabolites primarily involved in pro-
inflammatory actions, and conversely, n-3 PUFAs are widely recognized for their anti-
inflammatory capabilities [53].  
PUFAs occupy the sn-2 position of cell membrane phospholipids. Although cell 
membrane composition is regulated based on requirements for specific tissues, it is well 
established that increasing dietary consumption of certain PUFAs can subsequently elevate the 
concentration of that PUFA within cell membranes. This is particularly of interest with regard to 
n-3 PUFAs due to their anti-inflammatory roles and the concern for deficiency in typical 
Western diets. Insufficient intake of n-3 PUFAs can result in an imbalance that favors pro-
inflammatory mediators [54]. Conversely, consumption of fish oil supplements has been shown 
to elevate EPA and DHA concentrations in cell membranes of cells and tissues involved in 
inflammation, such as immune cells and adipose tissue, in both a time- and dose-dependent 
manner [55-58]. This increase in EPA and DHA coincides with a decrease in ARA [57, 58]. 
Thus, it is of great interest to examine how these alterations in membrane PUFAs and their 
metabolites can elicit various downstream effects on health. 
2.2.2. Eicosanoid Production 
 
Upon cleavage by calcium-activated phospholipase A2, PUFAs are liberated from cell 
membranes and become subject to metabolism by different classes of enzymes in order to form 
bioactive compounds known as eicosanoids. Three major enzyme classes metabolize PUFAs, 
including cyclooxygenases (COXs), lipoxygenases (LOXs), and cytochrome P450 (CYP) 
monooxygenases. ARA is the most prevalent PUFA in most cell membranes and therefore is the 
dominant substrate for eicosanoid synthesis. Metabolism of ARA by COXs produces 
prostaglandins (PGs) and thromboxanes (TXs). Among the most biologically relevant is PGE2, a 
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potent pro-inflammatory mediator that induces production of inflammatory cytokines by 
macrophages, such as tumor necrosis factor (TNF)a, interleukin (IL)-1b, and IL-6. Other key 
players include TXA2, an activator of platelet aggregation, and PGI2, involved in vasodilation 
and inflammation resolution. LOXs give rise to various leukotrienes (LTs), which are also 
pertinent in facilitation of the inflammatory response [48, 59].  
EPA is also capable of forming various PGs, TXs, and LTs upon metabolism by COXs 
and LOXs, although their biological potency is lesser than those derived from ARA and 
consequently, cytokine production and the overall inflammatory influence are attenuated [60]. 
Remarkably, both EPA and DHA can also produce a different class of eicosanoids when acted 
upon by COXs and LOXs that are anti-inflammatory and inflammation resolving, which are 
deemed as resolvins (from EPA and DHA), and protectins and maresins (from DHA) [48, 49, 
60]. Altered eicosanoid production is a key mechanism through which these long-chain n-3 
PUFAs confer benefits for chronic metabolic diseases. However, EPA and DHA exert additional 
contributory actions such as decreasing the expression of adhesion molecules involved in 
atherosclerosis development, limiting the production of pro-inflammatory transcription factors, 
cytokines, and angiogenic growth factors, and reducing lipogenesis via inhibition of sterol 
regulatory element binding protein 1c (SREBP1c) [48].  
The third pathway of eicosanoid formation, the CYP monooxygenase pathway, is less 
characterized than the COX and LOX pathways and has only recently begun to receive 
appreciable attention in the literature. CYP hydroxylases can hydroxylate at or near the methyl 
end of PUFAs to produce hydroxy fatty acids. Terminal hydroxylation of ARA forms 20-
hydroxyeicosatetraenoic acid (20-HETE), which has demonstrated pro-inflammatory 
capabilities. Elevated plasma and serum levels of this metabolite are associated with increased 
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incidence of metabolic disease [61]. CYP epoxygenases oxidize PUFAs across one of their 
double bonds, giving rise to various regioisomers of epoxy fatty acids (EpFAs). EpFAs produced 
from ARA are known as epoxyeicosatrienoic acids (EETs), whereas EPA and DHA are 
metabolized to epoxyeicosatetraenoic acids (EEQs) and epoxydocosapentaenoic acids (EDPs), 
respectively. 11,12-EET and 14,15-EET are the most abundantly generated regioisomers from 
ARA in most mammalian tissues. In the n-3 varieties, CYP epoxygenases preferentially oxidize 
the n-3 bond, resulting in 17,18-EEQ and 19,20-EDP being the predominant n-3 EpFAs formed 
[10]. EpFAs have sparked intrigue among researchers due to their observed anti-inflammatory 
actions and proposed benefits for numerous diseases [10-13]. The CYP epoxygenase pathway 
and its potential impacts for metabolic health will be discussed in greater detail in the following 
sections. 
2.2.3. CYP Epoxygenase Pathway: CYP Isoforms and Degradation by sEH 
 
CYP enzymes comprise a complex superfamily of genes, with 57 isoforms reported to be 
functional in humans [62]. These enzymes function to catalyze the metabolism of various 
xenobiotics and endogenous compounds. CYP enzymes are most highly expressed in the liver 
but are also expressed in various extrahepatic tissues such as the kidney, heart, skeletal muscle, 
adipose tissue, pancreas, and vasculature [63]. Isoforms belonging to the CYP2C and CYP2J 
subfamilies are considered the primary epoxygenases responsible for EpFA formation in 
mammals. Humans possess four CYP2C isoforms, which are CYP2C8, CYP2C9, CYP2C18, and 
CYP2C19 [10, 62]. Murine distribution of isoforms is increasingly complex with 15 described 
functional isoforms: Cyp2c29, Cyp2c37, Cyp2c38, Cyp2c39, Cyp2c40, Cyp2c44, Cyp2c50, 
Cyp2c54, Cyp2c55, Cyp2c65, Cyp2c66, Cyp2c67, Cyp2c68, Cyp2c69, and Cyp2c70 [10, 62, 64]. 
Humans only possess one CYP2J isoform, which is CYP2J2. In mice, once again, significant 
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allelic expansion has resulted in seven functional isoforms: Cyp2j5, Cyp2j6, Cyp2j8, Cyp2j9, 
Cyp2j11, Cyp2j12, and Cyp2j13 [10, 62, 65]. The wide variety of epoxygenase isoforms and 
inconsistencies between mice and human varieties creates additional layers of complexity in the 
effort to elucidate the key players driving formation of EETs and other EpFAs.  
 Soluble epoxide hydrolase (sEH) is a cytosolic enzyme whose C-terminal domain rapidly 
hydrolyzes EpFAs into their corresponding diols following their formation [66]. These diol 
counterparts, known as dihydroxyeicosatrienoic acids (DHETs) in the case of EETs, are much 
less biologically active and do not exert the same beneficial metabolic effects as EpFAs [10, 67]. 
In fact, certain diol products of sEH have even illustrated pro-inflammatory potential [61, 68]. 
EpFAs can be metabolized through other pathways [69]; however, hydrolysis by sEH represents 
the dominant pathway of metabolism [67]. Due to these observations, various pharmacological 
inhibitors of sEH have been generated in order to stabilize and enhance endogenous EpFA levels 
for therapeutic purposes with remarkable levels of efficacy demonstrated in a variety of 
conditions, including cardiac arrythmias, hypertension, atherosclerosis, chronic obstructive 
pulmonary disease, renal failure, and insulin resistance, among others [70]. 
2.2.4. Epoxy Fatty Acids: Functions and Mechanisms of Action 
 
EETs are by far the most heavily studied of the CYP-derived EpFAs, and therefore much 
of the evidence summarized here regarding EpFAs will be specific to EETs. EETs stimulate 
vasodilation, thrombolysis, angiogenesis, and cellular proliferation, and attenuate overall 
inflammation and nociception, acting through both autocrine and paracrine processes [63, 67, 
71]. EEQs and EDPs are also anti-inflammatory, anti-nociceptive, and vasodilatory, but these n-3 
derived epoxides differ from EETs in that they elicit anti-proliferative, proapoptotic, and anti-
angiogenic effects on target cells [63, 67, 71].  
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There are several mechanisms through which these EpFAs exert their biological actions. 
EETs are thought to bind to cell-surface receptors in order to activate downstream signal 
transduction pathways. For example, EET-dependent vasodilation occurs through activation of 
the cAMP/protein kinase A (PKA) pathway. Additional EET actions are mediated through 
activation of phosphatidylinositol 3-kinase (PI3K)/Akt, mitogen-activated protein (MAP) kinase, 
AMP-activated protein kinase (AMPK), and Src kinase signaling pathways, among others [67, 
72]. It has been suggested that a specific EET cell membrane receptor exists; however, there is 
currently little evidence to substantiate this claim and the supposed EET receptor has yet to be 
identified or cloned [67, 71].  
 EETs and DHETs can also be taken up directly by cells and incorporated into 
phospholipids through a coenzyme-A-dependent mechanism [67, 73, 74]. The physiological 
relevance of this incorporation into cell membranes remains to be determined, and it is thought 
this may provide an intracellular storage pool of EETs for later usage [71]. Cytosolic fatty acid 
binding proteins (FABPs) have been shown to bind EETs and may help to facilitate their uptake 
into cells [67, 75]. EETs attached to FABP are also protected from sEH-mediated hydrolysis, 
indicating this interaction may serve to prolong EET actions within the cell [76]. In addition to 
cell-surface interactions, EET actions are also mediated through interaction with various 
intracellular effectors such as ion channels and transcription factors [67]. Most notably, EETs 
have illustrated an ability to bind and activate the PPARs [77-80], which likely accounts for 
many of their observed metabolic benefits related to adipose tissue and inflammation. A detailed 
summary of the evidence surrounding EpFA generation in relation to adipose tissue and obesity 
is provided in the next section.  
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2.3. CYP Epoxygenase Pathway, White Adipose Tissue, and Obesity 
 
The potent anti-inflammatory capabilities of EpFAs have acquired significant attention 
for a potential therapeutic role in the progression of obesity and its associated metabolic diseases.  
The effects of EpFAs on body weight and cardio-metabolic health appear to be mediated through 
a variety of cell types and tissues in the body, including endothelial cells, hepatocytes, skeletal 
muscle, adipose tissue, and immune cells [10-13]. This section will focus particularly on the 
evidence pertaining to adipocyte-specific effects of the CYP pathway and the implications for 
obesity development. 
2.3.1. CYP and sEH Expression in White Adipose Tissue 
 
There are several observations that indicate obesity is associated with dysregulation of 
the CYP epoxygenase pathway in white adipose tissue. sEH expression is upregulated upon 
differentiation of 3T3-L1 preadipocytes into mature adipocytes while CYP epoxygenase 
expression is decreased [14, 81]. As expected, this corresponds with a stark decline in EET levels 
as adipocytes develop [14]. This observation is replicated at the human stem cell level, with 
CYP2J2 expression and EET levels being shown to decrease as human MSCs become mature 
adipocytes [82]. Elevated sEH expression is also present in the adipose tissue of HFD-fed mice 
and overweight humans when compared to lean controls, and total adipose sEH activity is higher 
in obese mice, even after normalization for body weight [81, 83]. Furthermore, CYP2J2 
expression decreased by 71% in the subcutaneous adipose tissue of obese women compared to 
lean women [84]. A comprehensive analysis of lipid mediators produced from the COX, LOX, 
and CYP pathways in adipose tissue of HFD-fed mice revealed that CYP-derived EpFAs are the 
most severely altered in obesity, with almost all types of EpFAs being reduced by 70-90% in the 
adipose tissue of obese mice [85]. Together, these observations provide compelling evidence that 
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adipocyte-specific expression of CYPs and sEH contribute to decreased EETs in obesity and 
implicate a therapeutic role for enhancing EpFA production in adipose tissue. There are three 
main approaches used to augment EpFA concentration in order to assess therapeutic outcomes: 
overexpression of CYP epoxygenase enzymes, administration of stable EET analogs, and 
inactivation of sEH through pharmacological inhibition or targeted gene deletion. The following 
sections will outline findings obtained in relation to white adipose tissue and obesity utilizing 
these tactics. 
2.3.2. CYP Epoxygenase Pathway: Adipogenesis and Obesity 
 
Sustained white adipogenesis is a hallmark of obesity, driving both hyperplasia and 
hypertrophy of white adipocytes in order to accommodate excess lipids. Key transcriptional 
mediators of this process include PPARg, CCAAT/enhancer-binding protein (C/EBP)a, and 
SREBP1c [14, 32]. Accumulating evidence suggests that EETs and other EpFAs elicit regulatory 
functions in relation to white adipogenesis. Administration of stable EET analogs dose-
dependently suppressed differentiation of 3T3-L1 preadipocytes and MSCs into mature 
adipocytes with reduced lipid accumulation and decreased gene expression of adipogenic 
markers, including PPARg, C/EBPa, SREBP1c, and fatty acid synthase (FAS) [14, 82]. 
Furthermore, EET analogs given to mice in the drinking water attenuated HFD-induced increases 
in body weight, fat mass, and adipocyte size, accompanied by an improvement in glucose 
tolerance [14]. Administration of sEH inhibitors and targeted gene deletion of Ephx2, the gene 
encoding for the sEH protein, has been shown to produce similar anti-adipogenic effects through 
an increase in EpFA bioavailability [14, 82, 86]. 
The suppressive effect of CYP-derived EpFAs on white adipogenesis is further 
corroborated by the study of Cyp2j4 deletion in rats and MSCs [87]. The epoxygenase Cyp2j4 is 
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expressed in the major rat organs and shares 79% homology with human CYP2J2 [88]. 
Remarkably, Cyp2j4-/- MSCs underwent spontaneous adipogenesis, in that these cells 
differentiated into mature adipocytes without the addition of adipogenic differentiation media, 
displaying significant lipid accumulation and expression of Fabp4. Moreover, WAT from 
Cyp2j4-/- rats exhibited elevated expression of PPARg and C/EBPa compared to wild-type (WT) 
control rats [87]. 
 CYP2J2 gene therapy in mice, which resulted in significant CYP2J2 protein expression in 
adipose tissue, was confirmed to elevate circulating EETs. Overexpression of this key human 
epoxygenase mitigated the burden of a HFD, with significantly reduced total body weight, 
adiposity, serum triglycerides and cholesterol in the transgenic mice [89]. These observed effects 
on cholesterol metabolism appear to be at least partially due to adipocyte-derived EpFAs, as  
incubation of 3T3-L1 differentiated adipocytes with an sEH inhibitor enhanced CD36-mediated 
recognition and degradation of oxidized low-density lipoproteins, and improved cholesterol 
efflux to form high-density lipoproteins through upregulation of ATP-binding cassette 
transporter (ABCA1) [90]. Moreover, this enhancement of reverse cholesterol transport through 
sEH inhibition was also demonstrated in adipocytes in vivo [91].  
However, effects on white adipose tissue are not solely due to adipocyte-specific EpFA 
production, as other studies have demonstrated similar outcomes mediated through epoxygenase 
overexpression in other organs. For example, a similar study examining CYP2J2 gene therapy in 
diabetic mice reported that CYP2J2 protein expression was primarily present in the liver, with no 
detectable levels in adipose tissue. Despite this, these transgenic mice still experienced a marked 
decrease in body weight, serum triglycerides, and cholesterol levels [92]. Moreover, endothelial-
specific overexpression of CYP2J2 in mice significantly attenuated HFD-induced increases in 
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body weight and adiposity when compared to WT controls, while also improving vascular 
dysfunction [93]. The anti-adipogenic effects of epoxygenase overexpression may be partially 
attributed to enhanced lipid oxidation, as endothelial CYP2J2 overexpression has also been 
shown to activate the AMPK pathway with increased phosphorylation of acetyl-CoA 
carboxylase (ACC) and increased expression of carnitine palmitoyltransferase I (CPT1) and 
PPARa [94]. The studies of endothelial-specific CYP2J2 overexpression implicate EpFAs from 
the endothelium may evoke paracrine effects on adipocytes. Given that endothelial cells 
comprise a significant portion of the adipose stromal vascular fraction [95], it is likely that 
EpFAs can arise from these neighboring cells in order to exert their functional effects in 
adipocytes.  
 It is important to note that physical outcomes of altering EpFA bioavailability in vivo on 
adiposity are not apparent until subjects are placed under significant metabolic stress from 
energy-dense diets or advancing age. While endothelial CYP2J2 overexpression in mice 
attenuated HFD-induced increases in body weight and adiposity compared to WT controls, no 
differences between groups were detected when mice were fed regular chow [94]. Similarly, 
these transgenic mice were also protected from aging-induced increases in fat mass and 
adipocyte size, but no differences in these parameters were present in the young mice [96]. 
Cyp2j4-/- rats fed a high-fat, high-sugar cafeteria diet (CAF) displayed increased body weight and 
fat mass gain with greater adipocyte size compared to WT rats fed the same diet, and these 
effects were also mirrored under the pressure of aging [87]. Together, these outcomes 
demonstrate the beneficial impacts of CYP epoxygenase enzymes on body weight and adiposity 
under circumstances of metabolic stress. 
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 EETs have been demonstrated to bind and activate PPARg, so it is rather surprising that 
the anti-adipogenic effect of increased EpFAs seems to be at least partially facilitated through 
downregulation of PPARg in WAT under metabolic stress, as summarized above. It has been 
speculated that EET interaction with ERK, AMPK, and cAMP/PKA signaling pathways may 
play a role to evoke this downregulation of adipogenic transcription factors, particularly in the 
early phases of adipogenesis [14]. However, the inhibitory effect of EETs and other EpFAs on 
white adipogenesis is not straightforward and some findings are even contradictory. One study 
demonstrated that EET analogs in the presence of an sEH inhibitor activated PPARg and 
increased Fabp4 mRNA expression in 3T3-L1 preadipocytes, a general marker of adipocyte 
differentiation [77]. Furthermore, CYP2J2 overexpression in the livers of diabetic mice increased 
PPARg mRNA and protein levels by 4.5-fold, potentially as a means to attenuate dyslipidemia 
present in diabetes [92]. Therefore, the effects of EpFAs on PPARg expression are likely 
contingent upon interaction of EpFAs with other signaling pathways and may be influenced by 
the tissue microenvironment, and further studies are needed to fully elucidate these complex 
interactions.  
2.3.3. CYP Epoxygenase Pathway: Inflammation in White Adipose Tissue 
Under circumstances of chronic energy surplus, the expansion of WAT exceeds the rate 
of neovascularization, resulting in a state of localized hypoxia and fibrosis. Reduced tissue 
plasticity and increased mechanical stress ultimately triggers a persistent inflammatory response, 
with altered adipokine secretion and infiltration of macrophages into adipose tissue. Further 
caloric overload eventually exceeds the storage capacity in WAT, leading to ectopic lipid 
accumulation in tissues such as the liver, skeletal muscle, and heart, a phenomenon commonly 
referred to as lipotoxicity. These alterations in adipocyte function and structure provoke the 
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downstream cardio-metabolic abnormalities characteristic of many chronic diseases, such as 
insulin resistance and endothelial dysfunction [97-100].  
In the inflammatory state, altered adipokine secretion is characterized by a stark increase 
in TNFa accompanied by a decline in adiponectin levels [97]. TNFa is known to stimulate the 
activation of nuclear factor kappa B (NF-kB), a central mediator of the inflammatory response 
that prompts expression of various pro-inflammatory genes [101]. Inhibition of NF-kB is a key 
mechanism through which EpFAs exert their anti-inflammatory actions [70]. EpFAs can block 
nuclear translocation of NF-kB through inhibition of IkB kinase and can also indirectly reduce 
its transcriptional activity through activation of PPARg [77, 80, 102]. CYP2J2 overexpression, 
sEH inhibition, and EET infusion via osmotic mini pumps have each demonstrated to mitigate 
HFD-induced activation of NF-kB and MAPK signaling pathways in WAT [89]. This function 
of EpFAs demonstrates a manner through which these lipid mediators can alleviate the 
inflammatory consequences of obesity within adipose tissue.  
Additionally, EpFAs have been shown to reverse the decline in adiponectin associated 
with inflammatory WAT. Adiponectin reduces inflammatory cytokines and oxidative stress and 
helps to regulate glucose and lipid metabolism [103]. Incubation of differentiated 3T3-L1 cells 
with an EET analog increased adiponectin levels in the culture medium and decreased the pro-
inflammatory cytokines IL-1a and IL-6 [104]. Similarly, treatment with an EET analog reversed 
the HFD-induced decrease of serum adiponectin in mice, with a reduction in serum TNFa and 
IL-6 [105]. Incubation of lipopolysaccharide (LPS)-induced 3T3-L1 mature adipocytes with an 
sEH inhibitor dose-dependently enhanced adiponectin levels, and this effect was blocked by the 
addition of the PPARg antagonist GW9662, indicating that upregulation of adiponectin occurs in 
a PPARg-dependent manner [90]. Furthermore, Cyp2j3 gene delivery in rats and 3T3-L1 cells 
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stressed by a HFD or thapsigargin resulted in increased adiponectin levels, which was mediated 
through alleviation of endoplasmic reticulum (ER) stress [106]. sEH inhibition or deficiency has 
also been reported to attenuate HFD-induced ER stress in the adipose tissue of mice [83].  
CYP2J2 overexpression and sEH inhibition have also been shown to reduce macrophage 
infiltration and fibrosis within the WAT of HFD-fed mice, with downstream effects on insulin 
sensitivity [89, 93, 107]. Furthermore, an increase in EpFA bioavailability through these means 
hindered the switch of macrophages to the classically active macrophage (M1) phenotype 
associated with WAT inflammation and preserved the alternatively activated macrophage (M2) 
phenotype. Conversely, Cyp2j4-/- rats fed CAF displayed increased crown-like structures and 
fibrotic collagen within WAT compared to WT mice on the same diet. These rats also 
experienced ectopic lipid accumulation particularly in the liver, indicative of severely overloaded 
and inflamed WAT [87]. Collectively, these findings indicate the anti-inflammatory activity of 
EETs and other EpFAs can ultimately aid in reversal of the altered adipokine production and 
macrophage infiltration characteristic of dysfunctional WAT, demonstrating ample significance 
for prevention of obesity-associated metabolic diseases.  
2.3.4. CYP Epoxygenase Pathway: Browning of White Adipose Tissue 
 
In addition to the anti-adipogenic and anti-inflammatory functions of EpFAs in WAT, 
these eicosanoids have also been reported to stimulate mitochondrial biogenesis and other 
markers of WAT browning. EETs and other EpFAs are thought to induce PGC-1a activation, 
resulting in downstream effects on mitochondrial function, thermogenesis, and overall energy 
expenditure. Stable EET analogs have been demonstrated to increase white adipocyte expression 
of PGC-1a, PRDM16, UCP1, uncoupling protein-2 (UCP2), and cytochrome c oxidase subunit 1 
(COX-1), both in vitro and in vivo [104, 108, 109, 110]. Additionally, EET analogs normalized 
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VO2 levels and the respiratory quotient in HFD-fed mice, with an elevation of mitochondrial 
proteins [108]. Outcomes on thermogenic and mitochondrial markers are PGC-1a-dependent, as 
these effects are diminished in PGC-1a-deficient cells and animals [104, 108, 109, 110]. CYP2J2 
overexpression and sEH inhibition also have been shown to elicit similar elevations in PGC-1a, 
UCP1, and UCP2 in WAT of HFD-fed mice [89, 93, 111]. Ultimately, the promotion of WAT 
browning is likely a manner through which EpFAs reduce adiposity under metabolic stress, 
working together with the other described anti-inflammatory and anti-adipogenic functions to 
combat obesity and its related diseases. 
2.4. CYP Epoxygenase Pathway and Brown Adipose Tissue 
 
2.4.1. Evidence for a Role in Brown Adipose Tissue 
 
Despite the described probable functions of EpFAs in browning and energy expenditure, 
studies examining the CYP pathway specifically in classical BAT are extremely limited. BAT is 
highly vascularized to facilitate substrate delivery and heat transmission, with endothelial cells 
representing the most abundant cell type within BAT [6].  Given that elevated EpFAs from the 
endothelium seemingly evoke paracrine effects on WAT, it can be presumed these endothelial-
derived EpFAs play additional roles in BAT.  
Brown adipocytes also produce EpFAs, which may contribute to favorable metabolic 
outcomes. Our recent data illustrated that sEH expression is upregulated in in vitro brown 
adipogenesis and in the BAT of diet-induced obese mice, mimicking the pattern observed in 
white adipocytes [112]. Furthermore, we found that sEH inhibition by trans-4-{4-[3-(4-
trifluoromethoxy-phenyl)-ureido]-cyclohexyloxy-benzoic acid (t-TUCB) dose-dependently 
promoted brown adipogenesis in vitro and increased protein expression of genes imperative for 
lipid metabolism in the BAT of diet-induced obese mice [112]. A different study examining sEH 
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inhibition in diet-induced obesity reported a 50% increase in UCP1 protein expression in the 
interscapular BAT (iBAT) of mice, accompanied by enhanced metabolic rate and weight loss 
[113]. Usage of a different sEH inhibitor in another study increased the iBAT mass of fat-1 mice, 
which are mice that express an n-3 desaturase that elevates endogenous cell membrane n-3 
PUFAs [107]. Additionally, EET analogs have been shown to upregulate UCP1 mRNA 
expression in the BAT of HFD-fed mice [14]. Collectively, these data indicate the beneficial 
metabolic effects of EpFAs may be partially mediated through enhanced BAT development and 
activation. 
It is worth noting that in the study which reported increased iBAT mass with an sEH 
inhibitor, the effect on BAT was only apparent in the fat-1 mice and not the WT mice [107]. 
These fat-1 mice presented with significantly elevated n-3-derived EpFAs due to increased cell 
membrane n-3 PUFAs, suggesting that n-3-derived EpFAs such as 17,18-EEQ and 19,20-EDP 
may be more important for the promotion of BAT development and activity rather than ARA-
derived EETs. This hypothesis is further substantiated when considering that fish oil is believed 
to enhance brown and beige fat development and thermogenesis based on numerous studies 
[114-118], and this may occur in an adipocyte-autonomous manner, given that EPA stimulates 
brown adipogenesis in vitro [119-121]. Primary mechanisms cited for these effects of fish oil 
include EPA- and DHA-mediated activation of TRPV1 and G protein-coupled receptor 120 
(GPR120) [122]. Perhaps, fish oil partially exerts these effects through increased formation of n-
3-derived EpFAs, potentially inducing more potent activation of TRPV1 and GPR120 with 
subsequent thermogenic stimulation. Indeed, it has been postulated that many of the 
cardioprotective properties of fish oil may be attributed to their epoxide metabolites [123], 
suggesting potential for a similar role in BAT. Elevation of cell membrane n-3 PUFAs from fish 
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oil supplementation has been shown to increase serum n-3 EpFAs more than any other lipid 
mediator [124], further validating the relevance of these eicosanoids in facilitating the effects of 
fish oil. Overall, it appears likely that EpFAs play a significant role in brown adipocytes, and 
further studies examining the CYP pathway in BAT are warranted to elucidate these functions 
and their relation to obesity pathogenesis. 
2.4.2. The Research Gap 
 
In summary, it has been well established that the CYP epoxygenase pathway holds 
therapeutic promise for obesity and its related metabolic diseases, and that these effects are 
administered at least partially in an adipocyte-autonomous manner. CYP overexpression is 
capable of producing these favorable outcomes through an increase in EpFA bioavailability. 
However, the vast array of CYP isoforms makes identification of the primary epoxygenases 
driving these metabolic effects to be much more complex and challenging. There are currently 
very limited data examining CYP expression in white adipocytes, and a comprehensive analysis 
of all known epoxygenase isoforms has not been conducted. Additionally, to our knowledge, no 
studies have determined which CYP isoforms are expressed specifically in BAT, and the role of 
CYP epoxygenase expression in brown adipogenesis has not yet been explored. 
 In this thesis, we sought to characterize adipocyte CYP epoxygenase expression 
throughout adipogenesis and in diet-induced obesity. This was accomplished through a 
comprehensive analysis of Cyp2j and Cyp2c mRNA expression in brown and white adipocytes 
of murine and human origin throughout differentiation, and in the BAT and WAT of mice fed 
HFD and regular chow. Furthermore, we began to elucidate the role of the CYP pathway in 
brown adipocytes through modulation of CYP epoxygenase expression in murine and human 
brown adipogenesis. Collectively, these data contribute to our understanding of the CYP 
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epoxygenase pathway in adipocytes and suggest a role of these enzymes in brown adipogenesis, 
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CHAPTER III  
MATERIALS AND METHODS 
 
3.1. Materials and Reagents 
 
Anti-UCP1 antibody was purchased from Sigma-Aldrich (St. Louis, MO). Anti-PGC-1a 
antibody was purchased from Millipore (Temecula, CA). Anti-CYP2J2 antibody was purchased 
from Kerafast (Boston, MA). Anti-PPARg, anti-Myc-Tag, anti-ERK1/2, horseradish peroxidase-
conjugated goat anti-rabbit, and horseradish peroxidase-conjugated goat anti-mouse antibodies 
were purchased from Cell Signaling Technology (Danvers, MA).  
The Myc-DDK-tagged Cyp2j13 cDNA plasmid and empty vector control (pCMV6) were 
purchased from OriGene (Rockville, MD). The lentiviral particles against mouse Cyp2j13 and a 
non-targeting scrambled control were obtained from MISSION Sigma-Aldrich (St. Louis, MO). 
The CYP2J2 cDNA plasmid was a gift from Dr. Ahmed Bettaieb at the University of Tennessee 
Knoxville, and the empty vector pSBtet-Pur was a gift from Eric Kowarz [125] (Addgene 
plasmid # 60507; http://n2t.net/addgene:60507; RRID:Addgene 60507). The pSBtet-Pur-CYP2J2 
construct was generated by PCR amplifying CYP2J2 full cDNA fragment flanked with two 
different SfiI sites followed by ligation into the SfiI pre-cut pSBtet-Pur vector. The complete 
CYP2J2 cDNA sequences in pSBtet-Pur were confirmed by sequencing.  
3.2. Cell Culture and Differentiation 
 
The murine brown preadipocyte cell line was a gift from Dr. Johannes Klein (University 
of Lubeck, Lubeck, Germany), and was generated from the interscapular brown adipose tissue of 
newborn C57BL/6J mice [126]. The cells were maintained in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 20% fetal bovine serum (FBS) (Atlanta Biologicals, 
Flowery Branch, GA) in a humidified 37ºC and 5% CO2 incubator until they reached confluence 
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(designated as day 0 (D0)). The cells were then induced to differentiate in differentiation media 
containing DMEM supplemented with 20% FBS, 1 nM T3, and 20 nM insulin every 2 days for 6 
days. Select cells received induction media containing differentiation media supplemented with 
0.125 mM indomethacin, 2 µg/ml dexamethasone, and 0.5 mM 3-isobutyl-1-methylxanthine 
(MIX) for 24 hours prior to being changed into differentiation media to induce a stronger degree 
of differentiation.  
 The murine 3T3-L1 cell line was obtained from ATCC (Manassas, VA). The cells were 
maintained in DMEM supplemented with 10% calf serum (Hyclone, Logan, UT) until they 
reached confluence. Preadipocytes were then induced to differentiate with differentiation media 
containing DMEM supplemented with 10% FBS, 1 µM dexamethasone, 10 µg/ml insulin, and 
0.5 mM MIX for 3 days (D0-D3). Media were subsequently changed to DMEM with 10% FBS 
and 10 µg/ml insulin for an additional 2 days (D4-D5). Cells were then maintained in DMEM 
with 10% FBS until fully differentiated on D7.  
 The human brown cell line was a gift from Dr. Yu-hua Tseng at Joslin Diabetes Center. 
Cells were cultured and differentiated, as previously described [127]. Briefly, the preadipocytes 
were cultured in DMEM supplemented with 10% FBS until confluency was achieved. Cells were 
then induced to differentiate in DMEM supplemented with 10% FBS, 0.5 µM insulin, 33 µM 
biotin, 17 µM pantothenate, 0.1 µM dexamethasone, 2 nM T3, 500 µM MIX, 30 µM 
indomethacin, and 5 µM rosiglitazone. Media were replaced every 3 days until cells were fully 
differentiated at 3 or 4 weeks. For the CYP2J2 overexpression experiments, human brown cells 
received either 1 µg/ml doxycycline or the vehicle control (water) in the media at 48 hours prior 
to confluency, and then with every medium change thereafter in order to induce stronger 
expression of human CYP2J2.  
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293T (human embryonic kidney cells) were obtained from Sam Lee at Beth Israel 
Hospital (Boston, MA) [128] and were used to generate positive controls for the CYP2J13 and 
CYP2J2 protein expression. The cells were maintained in DMEM with 10% FBS. 
3.3. Animals 
 
All mice studies were approved by the Institutional Animal Care and Use Committee at 
the University of Tennessee. C57BL/6J mice were purchased from Jackson Laboratory (Bar 
Harbor, ME). The diet-induced obese mice and their chow-fed controls have been described 
elsewhere [129, 130]. Briefly, six-week old male mice were fed either a HFD (60% kcal from 
fat, D12492) (Research Diets Inc., New Brunswick, NJ) or regular chow (RC) for 20 weeks 
before sacrifice at 26 weeks of age. Upon sacrifice, iBAT, epididymal and subcutaneous inguinal 
WAT (eWAT and iWAT) were excised and immediately snap-frozen in liquid nitrogen and 
stored at -80ºC until analysis. 
3.4. Lipofectamine Transfection 
 
 Murine and human brown preadipocytes were seeded in 12- or 6-well plates at ~50% 
confluency. Cells were then transfected using Lipofectamine 3000 and Plus reagent (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s instructions, and were split into selection media 
48 hours later. Cyp2j13-stably transfected murine brown preadipocytes were selected for two 
weeks with 600 µg/ml neomycin. Individual stable clones were used for analysis. CYP2J2-stably 
transfected human brown preadipocytes and 293T cells were selected for two weeks with 2 
µg/ml puromycin. Stably transfected pooled cells were used for analysis. 293T cells transfected 
with Cyp2j13 did not undergo selection and were immediately harvested at 48 hours after 
transfection. 
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3.5. Lentiviral shRNA Particle Infection 
 
Murine brown preadipocytes were seeded at ~50% confluency in 6-well plates. Cells 
were then transduced with lentiviral particles against mouse Cyp2j13 or a scrambled non-
targeting control (MISSION Sigma-Aldrich, St. Louis, MO) according to the manufacturer’s 
instructions, and were split into selection media after 48 hours. Stably infected cells were 
selected for two weeks with 600 µg/ml neomycin. Individual stable clones were used for 
analysis.  
3.6. RNA Preparation and Quantitative Real-Time PCR Analysis 
 
Total RNA was extracted using TRI reagent (Molecular Research Center, Cincinnati, 
OH) according to the manufacturer’s instructions. Total RNA yield was quantified with 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). Reverse 
Transcription was performed using a High Capacity cDNA Reverse Transcription Kit (Thermo 
Scientific, Pittsburgh, PA) according to the manufacturer’s instructions. mRNA expression of 
target genes and the housekeeping gene 36B4 (a ribosomal protein that is a component of the 
60S subunit) were measured quantitatively using the PowerUp SYBR master mix (Applied 
Biosystems, Austin, TX) and gene-specific primers (primer sequences available upon request). 
PCR reactions were run in a 96-well format using an ABI 7300HT instrument. Cycle conditions 
were 50ºC 2 min, 95ºC 2 min, 40 cycles of 95ºC for 15 s, then 60ºC for 1 min. Relative gene 
expression was calculated using the 2-DCt method, after normalization to the housekeeping gene 
36B4. 
3.7. Western Blot Analysis 
 
Total cell lysates were prepared using 1xRIPA lysis buffer (Cell Signaling, Danvers, 
MA). Protein concentrations were quantified using the BCA assay kit (Thermo Scientific, 
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Waltham, MA). Proteins were separated on a 10% SDS-PAGE gel and then transferred to 
polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA). Membranes were blocked in 
TBST buffer (20 mM Tris Base, 137 mM NaCl, and 0.1% Tween 20 (pH 7.4)) containing 5% 
nonfat milk. Membranes were then immunoblotted with the primary antibodies at 4ºC overnight, 
followed by 1-hour incubation with secondary antibodies conjugated with horseradish peroxidase 
at room temperature. Protein bands were visualized using SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Scientific, Pittsburgh, PA). Band densitometry was 
quantified using the ChemiDocXRS+ system with Image Lab software (Bio-Rad, Hercules, CA).  
3.8. Statistical Analysis 
 
Statistical analysis was performed using SigmaPlot 14.0 (Systat Software, San Jose, CA). 
One-way ANOVA followed by the Holm-Sidak method was performed in the time course 
studies to determine differences in group means compared to cells collected on day 0. Murine 
brown cells receiving induction media and those receiving only differentiation media were 
compared separately to day 0. One-way ANOVA followed by the Student-Newman-Keuls 
method for multiple groupwise comparisons was conducted to determine differences in group 
means compared to the control groups in the animal studies and Cyp2j13 overexpression and 
knockdown experiments. In the studies of CYP2J2 overexpression in human brown cells, two-
way ANOVA followed by the Student-Newman-Keuls method was performed to determine the 
differences between CYP2J2 overexpression and the empty vector controls and between 
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CHAPTER IV  




4.1.1. CYP Epoxygenase Expression in Murine Brown Adipocyte Differentiation 
 
We first examined CYP epoxygenase expression in murine brown adipocyte 
differentiation. Brown adipocyte marker genes Ucp1, Pgc-1a, Pparg, Prdm16, and cell death-
inducing DFFA like effector A (Cidea) were significantly increased in a time-dependent manner 
during the course of differentiation, and their expression were significantly higher in cells that 
received induction media (Figure 1A). mRNA expression of a total of 19 murine Cyp2j and 
Cyp2c isoforms (Cyp2j5, Cyp2j6, Cyp2j7, Cyp2j8, Cyp2j9, Cyp2j11, Cyp2j12, Cyp2j13, 
Cyp2c29, Cyp2c37, Cyp2c38, Cyp2c39, Cyp2c40, Cyp2c44, Cyp2c50, Cyp2c54, Cyp2c55, 
Cyp2c65, and Cyp2c66) were examined in the murine brown cells. Of these, Cyp2j5, Cyp2j7, 
Cyp2j11, Cyp2j12, Cyp2c29, Cyp2c38, and Cyp2c40 were not detectable in all or a majority of 
the time points examined. mRNA expression levels of the remaining Cyp2j isoforms and select 
Cyp2c isoforms during differentiation are shown (Figure 1B, C). Interestingly, expression of all 
the Cyp2j isoforms were either elevated or not changed in the cells receiving only differentiation 
media but suppressed in the more strongly differentiated cells that received induction media 
(Figure 1B). The cells receiving only differentiation media had statistically significant elevations 
in mRNA levels of Cyp2j6, Cyp2j9, and Cyp2j13 compared to day 0, with an upward trend also 
observed with Cyp2j8. Conversely, in the cells receiving induction media, mRNA expression of 
Cyp2j6, Cyp2j9, and Cyp2j13 significantly decreased compared to day 0, with a downward trend 
in Cyp2j8 mRNA levels. (Figure 1B).  
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Similar outcomes were observed in the Cyp2c isoforms, with slightly elevated or 
unaffected mRNA levels in cells receiving only differentiation media, and lower expression in 
cells receiving the induction media (Figure 1C). However, expression patterns were not as 
consistent between samples as with the Cyp2j isoforms. Of the tested isoforms, Cyp2c44 
displayed a unique expression pattern, which was significantly elevated both in cells receiving 
only differentiation media and receiving induction media (Figure 1C). mRNA levels of Cyp2c37, 
Cyp2c50, Cyp2c55, Cyp2c65, and Cyp2c66 were increased in cells receiving only differentiation 
media, reaching statistical significance for Cyp2c55 (p < 0.05). Similarly, mRNA levels of these 
Cyp2c isoforms showed a downward trend in cells receiving the induction media. Overall, these 
data demonstrate that mRNA levels of tested murine Cyp2j and 2c isoforms are inversely 
correlated with the degree of brown adipocyte differentiation, suggesting roles of these enzymes 
in brown adipogenesis.  
Next, we sought to compare the relative abundance of mRNA levels of the examined 
CYP isoforms both in the brown pre- and differentiated adipocytes. Of the Cyp2j isoforms, 
Cyp2j6 mRNA levels were the most abundant, followed by Cyp2j9, then Cyp2j13, and Cyp2j8. 
Cyp2c65 mRNA levels were the most abundant of the Cyp2c isoforms, followed by Cyp2c66, 
and Cyp2c55 expression was the least pronounced. Between both Cyp2j and Cyp2c subfamilies, 
Cyp2c65 was the most highly expressed (Figure 1D). 
4.1.2. CYP Epoxygenase Expression in 3T3-L1 Adipocyte Differentiation 
 After thoroughly studying CYP epoxygenase expression patterns in brown adipocyte 
differentiation, we then examined the expression of these genes in 3T3-L1 white adipocyte 
differentiation. Strong differentiation was indicated by time-dependent increases in mRNA levels 
of adipogenic markers Fabp4, Fasn, Pparg, C/ebpa, and stearoyl-Coenzyme A desaturase 1 
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(Scd1) during the course of differentiation (Figure 2A). Consistently, Cyp2j mRNA levels, 
except for Cyp2j8, appeared to be decreased at day 3 and 5 compared to that of day 0, but were 
increased by day 7, with statistically significant elevations observed in Cyp2j8 and Cyp2j13 (p < 
0.01) (Figure 2B). Interestingly, while majority of Cyp2j isoforms decreased at day 3, this 
regression appeared to be compensated for by an enhancement of Cyp2c mRNA expression. 
mRNA levels of Cyp2c37, Cyp2c50, Cyp2c55, Cyp2c65, and Cyp2c66 each showed pronounced 
and statistically significant elevations at day 3 (Figure 2C). The only tested isoform showing a 
different pattern was Cyp2c44, which increased throughout differentiation (Figure 2C). Similar 
to the Cyp2j isoforms but to a greater degree, expression of all the Cyp2c isoforms were elevated 
in the fully mature white adipocytes at day 7 compared to the preadipocytes (day 0). Overall, 
these data demonstrate that mRNA levels of tested murine Cyp2j and 2c isoforms are positively 
correlated with the degree of white adipocyte differentiation. Notably, the relative mRNA 
abundance of the tested CYP genes in the white adipocytes followed the same pattern as in the 
brown adipocytes, suggesting that similar CYP isoforms are the most prevalent EpFA producers 
in both brown and white adipocytes (Figure 2D). However, unlike the brown adipocytes, the 
relative Cyp2j6 mRNA level was overall the most abundant among both the Cyp2j and Cyp2c 
isoforms in the 3T3-L1 cells (Figure 2D).  
4.1.3. CYP Epoxygenase Expression in Human Brown Adipocyte Differentiation 
 After surveying CYP expression patterns in murine brown and white adipocytes, we next 
sought to examine the mRNA expression of human CYP isoforms in human brown adipocyte 
differentiation. The human brown preadipocytes achieved a high level of differentiation by week 
4, displaying significant increases in mRNA levels of brown adipocyte marker genes UCP1, 
PGC-1a, and PPARg (Figure 3A). Interestingly, mRNA levels of CYP2C isoforms were more 
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pronounced in the more differentiated state, with statistically significant elevations observed at 
week 4 in each of the four isoforms (Figure 3B). mRNA levels of CYP2C9 and CYP2C18 
showed approximately 50-fold increases of mRNA levels at week 4 compared to day 0 (p < 
0.001). This pattern contrasts slightly with the observed decline in Cyp2c mRNA levels in the 
murine brown cells receiving the induction media but aligns with the slight increase observed in 
the cells receiving only differentiation media. Considering these human brown cells did not fully 
differentiate to the extent of the murine brown cells receiving induction media, this observation 
suggests a bell-shaped pattern between CYP mRNA expression and brown adipocyte 
differentiation, in that enhanced mRNA levels are associated with a smaller degree of 
differentiation, but these levels are decreased as stronger degrees of differentiation are achieved. 
Interestingly, while CYP2C mRNA levels increased during human brown differentiation, 
CYP2J2 displayed an opposing pattern. CYP2J2 was found to be minimally expressed in our 
human brown cell line, and these low levels completely diminished with no detectable levels 
observed by week 4 (Figure 3B). Of the human CYP isoforms, CYP2C19 was the most abundant, 
followed by CYP2C18, then CYP2C9, CYP2C8, and finally CYP2J2 (Figure 3C). 
4.1.4. CYP Epoxygenase Expression in Diet-induced Obesity 
In order to characterize CYP expression patterns in adipose tissue under circumstances of 
metabolic dysfunction, we next examined relative mRNA levels of these enzymes in adipose 
tissue from HFD-induced obese mice compared to RC-fed controls. Interestingly, mRNA levels 
of Cyp2j isoforms in the iBAT trended upwards in HFD-fed mice compared to controls, but 
statistical significance was only achieved for Cyp2j9 (p < 0.05) (Figure 4A). Cyp2c mRNA 
expression in the iBAT displayed high levels of variation among individual mice and among 
isoforms (Figure 4B). There were no clear and consistent patterns across isoforms observed in 
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the eWAT, but Cyp2j6 mRNA expression was significantly elevated in the HFD-fed mice, 
whereas Cyp2c65 and Cyp2c66 mRNA levels were significantly suppressed (p < 0.05). Cyp2j13 
mRNA level also trended downwards, but this did not reach statistical significance (Figure 4C, 
D). In the iWAT, mRNA expression of Cyp2j isoforms again appeared to trend upwards in the 
HFD-fed mice, with Cyp2j8 reaching statistical significance (p < 0.05) (Figure 4E). No 
significant differences in iWAT Cyp2c mRNA levels were detected between groups (Figure 4F). 
Cyp2c55 expression was also examined in the tissue samples, but mRNA levels were primarily 
undetectable and therefore the data is not shown. Overall, these data suggest that obesity may be 
associated with dysregulation of CYP expression in different adipose tissue depots. 
4.1.5. Cyp2j13 Overexpression Suppresses Murine Brown Adipocyte Differentiation 
 Considering that Cyp2j isoforms displayed more consistent but differential mRNA 
expression patterns in brown vs. white adipocyte differentiation in the cell culture studies, we 
chose to specifically focus on Cyp2j isoforms in brown adipocyte differentiation for the next 
portion of our study. Cyp2j13 was selected for further investigation due to its unique mRNA 
expression pattern showing an upward trend in the iBAT and a downward trend in the eWAT of 
HFD-fed mice. We first examined the impact of Cyp2j13 overexpression on murine brown 
adipogenesis. CYP2J13 protein expression was increased by ~6-fold in the murine brown 
preadipocytes stably transfected with the Cyp2j13 expression plasmid (pCMV6-Cyp2j13) 
compared to preadipocytes stably transfected with the empty vector (pCMV6) (Figure 5A). At 
day 6 of differentiation, Cyp2j13 mRNA expression was increased by ~16-fold in the 
overexpressing murine brown adipocytes (Figure 5C). Remarkably, overexpression of this 
murine epoxygenase induced a strong suppression of brown adipocyte differentiation. At day 6 
of differentiation, Cyp2j13 overexpressed brown cells displayed significantly reduced lipid 
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accumulation (Figure 5B left panel) with an approximate 50% decrease in oil red O (ORO) 
absorbance (p < 0.001) (Figure 5B right panel). Furthermore, mRNA expression of key brown 
marker genes Ucp1 and Cidea and general adipocyte differentiation markers Pparg and Fabp4 
were significantly suppressed with Cyp2j13 overexpression (p < 0.01, p < 0.001, and p < 0.05, 
respectively) (Figure 5C). Protein levels of UCP1 and PPARg were also consistently suppressed 
in the Cyp2j13 overexpressing cells (p < 0.001). In contrast, mRNA expression of the 
thermogenic marker Pgc-1a was significantly elevated in the Cyp2j13 overexpressing cells 
(Figure 5C), but protein expression was significantly reduced (p < 0.05) (Figure 5D), suggesting 
differential regulation of Pgc-1a expression at the mRNA and protein levels by Cyp2j13 
overexpression in brown adipocytes. Ppara mRNA levels also trended downwards in the 
Cyp2j13 overexpressing cells, but this did not reach statistical significance (Figure 5C). 
Together, these findings suggest that increasing Cyp2j13 expression may repress brown 
adipocyte differentiation.    
4.1.6. Cyp2j13 Knockdown Enhances Murine Brown Adipocyte Differentiation 
We next utilized lentiviral-mediated knockdown of Cyp2j13 to assess if the opposite 
outcome could be produced. Due to the lack of an available antibody specific for CYP2J13, 
knockdown efficacy was validated solely on the mRNA level. mRNA expression of Cyp2j13 in 
the Cyp2j13 knockdown (KD) brown preadipocytes was reduced by ~70% compared to cells 
infected with the scrambled non-targeting control (p < 0.01) (Figure 6A). mRNA expression of 
the brown marker gene Cidea and general differentiation markers Fabp4 and Fasn were 
significantly enhanced in the Cyp2j13 KD cells on day 6 of differentiation (p < 0.001, p < 0.05, 
and p < 0.01, respectively) (Figure 6B). Pgc-1a mRNA expression also trended upwards, and 
PGC-1a protein levels displayed a significant elevation (p < 0.001) (Figure 6B, C). There were 
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no observed differences in Ucp1 mRNA expression between the two cell populations, however, a 
significant increase in UCP1 protein expression was observed (p < 0.01) (Figure 6C). In contrast, 
mRNA levels of both Pparg and Ppara were significantly reduced in the Cyp2j13 KD cells (p < 
0.01), but protein levels of PPARg were unaffected. Overall, these data appear to corroborate the 
suppressive effect of Cyp2j13 overexpression on brown adipogenesis and suggest that Cyp2j13 
may be a negative regulator of murine brown adipogenesis. 
4.1.7. CYP2J2 Overexpression Does Not Affect Human Brown Adipocyte Differentiation 
In attempt to gain insight into the role of CYP epoxygenases in human brown 
adipogenesis, we next analyzed the impact of CYP2J2 overexpression on human brown 
adipocyte differentiation. Human brown preadipocytes were stably transfected with the CYP2J2 
expression plasmid (pSBtet-CYP2J2) or the empty vector (pSBtet). Robust CYP2J2 expression 
was induced by treatment with 1 µg/ml doxycycline and compared with cells receiving the 
vehicle control (water). After 48 hours of treatment with doxycycline or water, only the human 
brown preadipocytes transfected with CYP2J2 and treated with doxycycline demonstrated 
significant CYP2J2 protein expression (Figure 7A). However, mRNA analysis in the human 
brown adipocytes after differentiation for three weeks demonstrated that cells transfected with 
the CYP2J2 plasmid still displayed a significant induction of CYP2J2 mRNA expression without 
doxycycline, although not to the extent of the cells which received doxycycline. Of the CYP2J2 
transfected cells, those receiving water experienced a ~2600-fold increase in CYP2J2 mRNA 
expression compared to the empty vector controls treated with water, while cells treated with 
doxycycline displayed nearly a 195,000-fold increase (p < 0.001) (Figure 7B). These strong 
elevations of CYP2J2 expression in the differentiated human adipocytes were also confirmed at 
the protein level (Figure 7C). Surprisingly, despite the highly successful induction of CYP2J2 
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overexpression in the human brown adipocytes, no visible differences in differentiation potential 
were observed between the four groups after differentiation for three weeks. CYP2J2 
overexpression did not change UCP1, PPARg, FABP4, FASN, or PPARa mRNA expression 
levels. However, CYP2J2 overexpression did elicit a significant reduction in PGC-1a mRNA 
levels compared to the empty vector controls (p < 0.05). Protein expression of PPARg was 
significantly increased with CYP2J2 overexpression (p < 0.01), but there were no changes in 
PGC-1a or UCP1 protein levels compared to the empty vector controls.  There were no 
significant alterations observed between the CYP2J2 overexpressing cells receiving doxycycline 
or water, suggesting that increasing CYP2J2 expression beyond the extent observed in the cells 
treated with water may not be sufficient to confer further changes in gene and protein expression, 
at least in the markers that were tested. These data suggest that overexpression of CYP2J2 may 
not be sufficient to affect human brown adipocyte differentiation. 
4.2. Discussion 
 
BAT has recently emerged as a novel target for treatment of obesity and its related 
metabolic disorders. Accumulating evidence suggests that CYP epoxygenase overexpression 
may confer benefits for metabolic disease, presumably due to increased EpFA bioavailability, 
but it is unknown if CYP epoxygenase overexpression directly affects brown adipogenesis and 
whether the beneficial effects of CYP epoxygenase overexpression in metabolic diseases are 
partially mediated through enhanced BAT development and activation. Increasing EpFA 
concentrations in white adipocytes has been shown to inhibit white adipocyte differentiation [14, 
82], suggesting these epoxygenase enzymes may play a regulatory role in adipogenesis. 
However, to our knowledge, adipocyte-specific expression of CYP epoxygenases has not been 
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extensively analyzed, and no studies on CYP epoxygenase expression and brown adipocyte 
differentiation have been reported. 
This study is the first to report CYP epoxygenase expression patterns throughout the 
course of adipocyte differentiation. We show that similar CYP isoforms (Cyp2j6, Cyp2j9, 
Cyp2j13, Cyp2c44, Cyp2c65, Cyp2c66) are the most highly expressed in both murine brown and 
white adipocytes, suggesting that these isoforms are the key drivers of murine adipocyte EpFA 
production. Furthermore, we show that CYP epoxygenase expression is higher in mature 
adipocytes vs. preadipocytes, except in the most strongly differentiated murine brown 
adipocytes, suggestive of a bell-shaped pattern in relation to adipocyte differentiation and 
epoxygenase expression levels. A previous study showed that Cyp2j9 and Cyp2c55 expression 
slightly decreased in mature white adipocytes compared to the preadipocytes [14]. It is possible 
that degrees of white adipocyte differentiation may be different between our model and the 
published study. Further studies are needed to confirm the expression patterns of Cyp2j and 2c 
isoforms in murine brown and white adipogenesis.  
We also demonstrated that Cyp2j mRNA levels showed an upward trend in the iBAT of 
HFD-fed mice. Given that obesity is associated with reduced BAT mass and activity [22], this 
finding seems to suggest that elevated Cyp2j expression is also associated with reduced BAT 
mass and activity, which seemingly aligns with our finding that Cyp2j mRNA levels were 
suppressed in more strongly differentiated brown adipocytes. Together, this implicates that 
Cyp2j may be a negative regulator for brown adipocyte development. This suspected impact of 
Cyp2j expression on brown adipogenesis was further validated by our studies of Cyp2j13 
overexpression and knockdown, which significantly suppressed and promoted brown adipocyte 
differentiation, respectively. Previous studies have shown that Cyp2j13 is highly expressed in 
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mouse kidneys and hearts, but not detectable in the liver [64, 131, 132]. Overall, however, this 
epoxygenase isoform is largely unexplored, and we are the first to closely examine its expression 
in adipose tissue. Our data strongly indicates that Cyp2j13 in adipose tissue plays a critical role 
in brown adipogenesis and may be a novel target for obesity treatment and prevention.  
Sustained white adipogenesis is integral in the initiation and progression of obesity and 
its related diseases. EET analogs have been shown in multiple studies to suppress white 
adipocyte differentiation [14, 82, 86], and knockout of the major rat epoxygenase Cyp2j4 in 
MSCs resulted in spontaneous adipogenesis, in that the MSCs became mature adipocytes without 
the addition of adipogenic media [87]. These data indicate that EpFAs inhibit white 
adipogenesis; however, it has been speculated that these lipid mediators elicit opposing effects 
on brown adipogenesis. We have demonstrated that sEH inhibition by t-TUCB dose-dependently 
promotes brown adipogenesis in vitro [112]. Another study utilizing a different sEH inhibitor 
also reported enhanced iBAT mass in fat-1 mice which express an n-3 desaturase that elevates 
endogenous n-3 PUFAs [107]. It has been suggested that this enhanced brown differentiation 
was a result of EpFA stabilization by sEH inhibition. However, results of the current study 
suggest that perhaps the promotion of brown adipogenesis by t-TUCB and other sEH inhibitors 
may be primarily attributed to their off-target effects, and not simply the inhibition of the EpFA-
degrading enzyme. It is worth noting that in our previous study, t-TUCB was also shown to 
activate both PPARg and PPARa in the brown preadipocytes in vitro [112], so it cannot be ruled 
out that the promotion of cellular brown adipogenesis by t-TUCB was a direct result of its 
activation of the PPARs and their downstream target genes, and not due to EpFA actions. 
Cyp2j13 epoxygenase overexpression presumably elevates EpFAs, implicating a similar 
suppressive effect of these lipid mediators on both brown and white adipogenesis. A comparable 
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influence of EpFAs on differentiation of both adipocyte types is certainly possible, considering 
that both brown and white adipocyte differentiation are under the master regulation of PPARg, 
and both cell types express similar CYP epoxygenase isoforms and exhibit an upregulation of 
sEH expression throughout differentiation [81, 112]. However, a limitation in our current study 
is that we did not measure the effect of Cyp2j13 expression on EpFAs, so we cannot definitively 
state that the observed suppression of brown adipogenesis is attributed to enhanced EpFAs. 
Studies directly examining the effect of EpFAs and stable analogs on cellular brown 
adipogenesis are warranted to further elucidate the role of the CYP epoxygenase pathway in 
brown adipocyte development and activation.  
It is also important to mention that it is unknown if differing EpFAs may elicit 
contrasting effects on brown adipocytes, which may impact the observed effects of CYP 
overexpression, since we are unsure of how the EpFA profile of the cells were affected in our 
studies. There are some discrepancies in functions between the n-6-derived EETs and the n-3 
varieties. For example, EETs are recognized as more proliferative and angiogenic, while EEQs 
and EDPs exert opposing actions [67]. There is substantial evidence proposing a role of fish oil 
in the promotion of brown adipogenesis [114-121], and it has been speculated that many of the 
suggested benefits of fish oil in cardiovascular disease and other conditions may actually be 
attributed to their epoxide derivatives [123]. Perhaps, addition of EPA or DHA as substrates in 
conjunction with CYP overexpression may produce opposite effects on brown differentiation 
than what was observed in our study.  
 Ultimately, the exact mechanism through which Cyp2j13 overexpression inhibits brown 
adipogenesis remains to be determined. It is likely this suppression occurs through a similar 
manner in which EETs inhibit white adipogenesis as shown in other studies. A previous study 
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postulated that EETs elicit anti-adipogenic effects by specifically targeting signaling events in 
the early phase of adipogenesis, as administration of EET analogs solely in the later phases 
diminished the suppressive effect [14]. In the early phases of preadipocyte differentiation, 
inhibition of the ERK signaling pathway and activation of the cAMP/PKA and AMPK signaling 
pathways have been shown to inhibit differentiation of 3T3-L1 cells with repression of PPARg, 
C/EBPa, and SREBP1c activation [133-135]. Increased EETs through epoxygenase 
overexpression or administration of stable analogs has been shown to inhibit ERK 
dephosphorylation in endothelial cells, activate AMPK in the liver, skeletal muscle, aorta, and 
kidney, and activate the cAMP/PKA pathway in the vasculature [15, 82, 94, 136, 137]. Thus, we 
can hypothesize that CYP-derived EETs and other EpFAs are involved in complex interactions 
with a variety of signaling pathways that ultimately suppress adipogenic transcription factor 
networks, particularly in the early phases of brown adipogenesis.  
   There is also question as to whether all Cyp2j isoforms possess the ability to inhibit 
brown differentiation, or if this is unique to certain isoforms, such as Cyp2j13. A previous study 
analyzed expression of all murine Cyp2j and Cyp2c isoforms in the liver, duodenum, kidney, and 
brain in response to LPS-induced inflammation, and reported that changes in mRNA expression 
levels were both isoform- and tissue-specific [132]. This strengthens the idea that although each 
of the Cyp2j and Cyp2c isoforms likely possess epoxygenase ability, their overall effect on 
cellular physiological processes may differ between isoforms and tissues. It would be beneficial 
to examine overexpression and knockdown of other CYP isoforms in brown adipocytes in order 
to compare effects on differentiation potential. Cyp2j6 may be an interesting candidate to 
explore, as it is the most abundant murine Cyp2j isoform in adipose tissue based on our data and 
the official homolog to human CYP2J2 [138]. Of the Cyp2c genes, analysis of Cyp2c44 
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overexpression could be noteworthy based on its unique expression patterns compared to the 
other Cyp2c isoforms, suggesting it may play a distinctive role in cellular processes.   
CYP2J2 overexpression did not significantly affect human brown adipocyte 
differentiation based on the markers analyzed. However, it is possible that CYP2J2 
overexpression produced effects on target genes that were not examined in the current study, 
such as those involved in inflammation and oxidative stress. CYP2J2 overexpression has been 
shown to attenuate HFD-and aging-induced increases in body weight, adiposity, serum lipids, 
insulin resistance, and vascular dysfunction [89, 92, 93, 94, 96]. Primary mechanisms reported 
for these outcomes include activation of PPARg, AMPK, and PI3K/Akt pathways, resulting in 
reduced inflammation, increased glucose uptake, and enhanced lipid metabolism. Endothelial-
specific CYP2J2 overexpression has been shown to improve dyslipidemia through activation of 
AMPK and elevation of PPARa expression [94]. In our study, however, there were no 
significant changes in PPARa mRNA expression with CYP2J2 overexpression in the human 
brown cells. Perhaps, this can be attributed to the lack of metabolic stress, as alterations in 
markers of lipid metabolism were only present in the CYP2J2 overexpressing mice when fed a 
HFD [94]. In fact, many of the beneficial metabolic effects of CYP2J2 overexpression previously 
reported are only apparent when subjects are placed under metabolic stress such as a HFD or 
aging, with no differences observed in the basal state. Much like white adipocytes, brown 
adipocytes are also capable of producing pro-inflammatory cytokines under circumstances of 
metabolic stress, and accumulating evidence suggests that inflammation can directly alter BAT 
development and thermogenic activity [139, 140]. We have previously shown that activation of 
Toll-like receptor (TLR)4, TLR2, or nucleotide-oligomerization domain-containing protein 
(NOD)1 in brown adipocytes induces inflammation and impairs UCP1 expression and 
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mitochondrial respiration [129]. Although CYP2J2 overexpression did not remarkably affect the 
expression of brown marker genes in the basal state, it would be intriguing to examine if CYP2J2 
overexpression may help alleviate inflammation-induced suppression of brown adipocyte 
differentiation and activity.  
It is also important to discuss the complex interactions of CYP epoxygenases and 
PPARg expression. Despite reported suppressive effects of EETs on white adipogenesis, their 
involvement in this process is not straightforward and some findings are contradictory to this 
notion. EETs have been shown to bind and activate PPARg, the master regulator of both brown 
and white adipocyte differentiation [77]. PPARs heterodimerize with RXR and bind to PPREs in 
target genes, such as UCP1 in brown adipocytes, in order to regulate their expression [33]. 
Rosiglitazone, a synthetic ligand for PPARg, has been shown to enhance brown adipocyte 
differentiation [141]. Although EETs have demonstrated to be PPARg ligands, data regarding the 
effect of EETs and CYPs on PPARg expression are still unclear. EETs have been shown to 
repress PPARg expression in white adipocyte differentiation [14, 82, 93]. However, another 
study demonstrated that EET analogs in the presence of an sEH inhibitor activated PPARg and 
increased Fabp4 mRNA expression in 3T3-L1 preadipocytes, a general marker of adipocyte 
differentiation [77], suggesting the effects of EETs on white adipogenesis are not straightforward 
and may depend on the cellular conditions and interactions with other signaling pathways. In our 
current study, Cyp2j13 overexpression significantly suppressed PPARg mRNA and protein 
expression in the differentiated murine brown adipocytes. However, knockdown of this gene also 
resulted in significant reduction of Pparg mRNA expression, and protein levels were not 
affected. Conversely, CYP2J2 overexpression did not affect PPARg mRNA levels, but 
significantly increased its protein expression. These findings highlight the complex nature of 
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CYP epoxygenase interaction with PPARg expression and indicate that the effect of CYPs on 
PPARg expression levels may be variable depending on the tissue microenvironment. Further 
studies are needed to define the effects of the CYP epoxygenase pathway on PPARg expression 
in different adipose tissue depots and under circumstances of metabolic stress. 
 In conclusion, the results presented in the current study help to characterize CYP 
epoxygenase expression in adipocytes and suggest that Cyp2j13 is a critical epoxygenase 
involved in the regulation of murine brown adipogenesis. Our findings indicate that EETs and 
other EpFAs may suppress brown adipogenesis through a similar manner in which these lipid 
mediators suppress white adipogenesis. Although CYP2J2 overexpression did not remarkably 
affect the expression of brown marker genes in the basal state, further studies are warranted to 
examine if CYP2J2 overexpression may help alleviate inflammation-induced suppression of 
brown adipocyte differentiation and activity. Moreover, the roles of CYP2J2 should be further 
investigated by gene knockdown and pharmacological antagonism. Additional studies analyzing 
other CYP epoxygenase isoform overexpression and knockdown are necessary to generate a 
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Figure 1. CYP epoxygenase expression in murine brown adipocyte differentiation 
 
Murine brown preadipocytes were induced to differentiate for 6 days. Total RNA samples were 
collected on day 0, day 2, day 4, and day 6. Upon initiation of differentiation, select cells 
received induction media for 24 hours (indicated as the day collected + I) to induce a stronger 
degree of differentiation. mRNA expression was quantified relative to the loading control 36b4 
and is displayed as fold of the day 0 samples (A, B, C).  (A) Relative mRNA expression of 
brown adipocyte marker genes Ucp1, Pgc-1a, Pparg, Prdm16, and Cidea. (B) Relative mRNA 
expression of Cyp2j epoxygenase genes Cyp2j6, Cyp2j8, Cyp2j9, and Cyp2j13. (C) Relative 
mRNA expression of Cyp2c epoxygenase genes Cyp2c37, Cyp2c44, Cyp2c50, Cyp2c55, 
Cyp2c65, and Cyp2c66. (D) Total mRNA abundance of Cyp2j and Cyp2c genes on day 0 and 
day 6 of differentiation, relative to 36b4. Data = Mean ± SEM (n=3). *, **, ***, p < 0.05, p < 
0.01, and p < 0.001, respectively, differentiation only groups compared to day 0 and induction 
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Figure 2. CYP epoxygenase expression in 3T3-L1 adipocyte differentiation 
 
3T3-L1 preadipocytes were induced to differentiate for 7 days. Total RNA samples were 
collected before each media change on day 0, day 3, day 5, and day 7. mRNA expression was 
quantified relative to the loading control 36b4 and is displayed as fold of the day 0 samples (A, 
B, C). (A) Relative mRNA expression of adipocyte differentiation marker genes Fabp4, Fasn, 
Pparg, C/ebpa, and Scd1. (B) Relative mRNA expression of Cyp2j epoxygenase genes Cyp2j6, 
Cyp2j8, Cyp2j9, and Cyp2j13. (C) Relative mRNA expression of Cyp2c epoxygenase genes 
Cyp2c37, Cyp2c44, Cyp2c50, Cyp2c55, Cyp2c65, and Cyp2c66. (D) Total mRNA abundance of 
Cyp2j and Cyp2c genes on day 0 and day 7 of differentiation, relative to 36b4. Data = Mean ± 
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Figure 3. CYP epoxygenase expression in human brown adipocyte differentiation 
 
Human brown preadipocytes were induced to differentiate for four weeks. Total RNA samples 
were collected on day 0, week 1, week 2, week 3, and week 4 of differentiation. mRNA 
expression was quantified relative to the loading control 36B4 and is displayed as fold of the day 
0 samples (A, B). (A) Relative mRNA expression of brown adipocyte marker genes UCP1, 
PGC-1a, and PPARg. (B) Relative mRNA expression of human CYP epoxygenase genes 
CYP2J2, CYP2C8, CYP2C9, CYP2C18, and CYP2C19. (C) Total mRNA abundance of CYP 
epoxygenase genes on day 0 and week 4 of differentiation, relative to 36B4. Data = Mean ± SEM 
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Figure 4. CYP epoxygenase expression in diet-induced obesity 
 
Six-week old C57BL/6J mice were fed with either a high-fat diet (60% kcal from fat) or a 
regular chow diet for 20 weeks, before being sacrificed at 26 weeks of age. iBAT, eWAT, and 
iWAT were collected and total RNA was isolated. mRNA expression was quantified relative to 
the loading control 36b4 and is displayed as fold of the regular chow fed controls. (A) Relative 
mRNA expression of Cyp2j genes in iBAT (n=7). (B) Relative mRNA expression of Cyp2c 
genes in iBAT (n=7). (C) Relative mRNA expression of Cyp2j genes in eWAT (n=6). (D) 
Relative mRNA expression of Cyp2c genes in eWAT (n=6). (E) Relative mRNA expression of 
Cyp2j genes in iWAT (n=6). (F) Relative mRNA expression of Cyp2c genes in iWAT (n=6). 
Data = Mean ± SEM. *, **, ***, p < 0.05, p < 0.01, and p < 0.001, respectively, compared to the 
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Figure 5. Cyp2j13 overexpression suppresses murine brown adipocyte differentiation 
 
Murine brown preadipocytes were stably transfected with the Myc-DDK-tagged Cyp2j13 
expression plasmid or the empty vector (pCMV6). Stably transfected cells were selected for two 
weeks with neomycin. Individual clones were selected and expanded to assess differentiation 
potential. Cells were stained and total RNA and protein samples were collected on day 6 of 
differentiation for analysis. mRNA expression was quantified relative to the loading control 
36b4. Densitometry of protein bands were normalized to the loading control ERK1/2 or non-
specific bands. Data are displayed as fold of the empty vector controls. (A) Protein bands and 
densitometry for Myc-tagged CYP2J13 in the murine brown preadipocytes (n=1). (B) ORO 
stained cell morphology and ORO absorbance for the differentiated adipocytes (n=3). (C) 
Relative mRNA expression of Cyp2j13, Ucp1, Pgc-1a, Cidea, Pparg, Fabp4, Fasn, and 
Ppara in the differentiated adipocytes (n=6). (D) Protein bands and densitometry for UCP1, 
PGC-1a, PPARg and ERK1/2 in the differentiated adipocytes (n=3). Data = Mean ± SEM. *, **, 
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Figure 6. Cyp2j13 knockdown enhances murine brown adipocyte differentiation 
 
Murine brown preadipocytes were transduced with lentiviral particles against Cyp2j13 or a 
scrambled non-targeting control. Stably infected cells were selected for two weeks with 
neomycin. Individual clones were selected and expanded to assess differentiation potential. Total 
RNA and protein samples were collected on day 6 of differentiation for analysis. mRNA 
expression was quantified relative to the loading control 36b4. Densitometry of protein bands 
were normalized to the loading control ERK1/2. Data are displayed as fold of the non-targeting 
controls. (A) Relative Cyp2j13 mRNA expression in the murine brown preadipocytes. (B) 
Relative mRNA expression of Ucp1, Pgc-1a, Cidea, Pparg, Fabp4, Fasn, and Ppara in the 
differentiated adipocytes. (C) Protein bands and densitometry for UCP1, PGC-1a, PPARg, and 
ERK1/2 in the differentiated adipocytes. Data = Mean ± SEM (n=3). *, **, ***, p < 0.05, p < 
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Figure 7. CYP2J2 overexpression does not affect human brown adipocyte differentiation 
 
Human brown preadipocytes were transfected with the CYP2J2 expression plasmid or the empty 
vector (pSBtet). Stably transfected cells were selected for two weeks with puromycin. At 48 
hours prior to confluency and at every media change thereafter, cells received either 1 µg/ml 
doxycycline to induce stronger expression of CYP2J2, or the vehicle control (water). Total RNA 
and protein samples were collected on week 3 of differentiation for analysis. mRNA expression 
was quantified relative to the loading control 36B4. Densitometry of protein bands was 
normalized to the loading control ERK1/2. Data are displayed as fold of the empty vector 
controls without doxycycline. (A) Validation of CYP2J2 overexpression in human brown 
preadipocytes after 48 hours treatment with doxycycline or water.  (B) Relative mRNA 
expression of CYP2J2, UCP1, PGC-1a, PPARg, FABP4, FASN, and PPARa in the differentiated 
human brown adipocytes (C) Protein bands for UCP1, PGC-1a, PPARg, CYP2J2 and ERK1/2 in 
the differentiated human brown adipocytes. Densitometry for UCP1, PGC-1a, and PPARg is 
shown. Data = Mean ± SEM (n=3). *, **, ***, p < 0.05, p < 0.01, and p < 0.001, respectively, 
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